PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
NYSE:MD - New York Stock Exchange, Inc. - US58502B1061 - Common Stock - Currency: USD
We assign a fundamental rating of 5 out of 10 to MD. MD was compared to 103 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of MD get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on MD. With these ratings, MD could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
MD had positive earnings in the past year.
In the past year MD had a positive cash flow from operations.
In multiple years MD reported negative net income over the last 5 years.
In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 5.23%, MD is doing good in the industry, outperforming 79.61% of the companies in the same industry.
The Return On Equity of MD (13.18%) is better than 82.52% of its industry peers.
MD's Return On Invested Capital of 9.55% is amongst the best of the industry. MD outperforms 80.58% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 9.38%.
The last Return On Invested Capital (9.55%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROIC | 9.55% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
The Profit Margin of MD (5.66%) is better than 80.58% of its industry peers.
With an excellent Operating Margin value of 10.97%, MD belongs to the best of the industry, outperforming 81.55% of the companies in the same industry.
In the last couple of years the Operating Margin of MD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
MD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MD has more shares outstanding
Compared to 1 year ago, MD has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 1.87 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.87, MD perfoms like the industry average, outperforming 47.57% of the companies in the same industry.
The Debt to FCF ratio of MD is 2.68, which is a good value as it means it would take MD, 2.68 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.68, MD belongs to the best of the industry, outperforming 80.58% of the companies in the same industry.
MD has a Debt/Equity ratio of 0.70. This is a neutral value indicating MD is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.70, MD is in line with its industry, outperforming 50.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Altman-Z | 1.87 |
ROIC/WACC1.05
WACC9.06%
2.3 Liquidity
A Current Ratio of 1.80 indicates that MD should not have too much problems paying its short term obligations.
With a decent Current ratio value of 1.80, MD is doing good in the industry, outperforming 66.02% of the companies in the same industry.
MD has a Quick Ratio of 1.80. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a Quick ratio of 1.80. This is in the better half of the industry: MD outperforms 66.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 53.39% over the past year.
MD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.01% yearly.
MD shows a decrease in Revenue. In the last year, the revenue decreased by -3.08%.
Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 2.49% on average per year.
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
3.2 Future
The Earnings Per Share is expected to grow by 1.39% on average over the next years.
The Revenue is expected to grow by 2.24% on average over the next years.
EPS Next Y15.09%
EPS Next 2Y8.97%
EPS Next 3Y6.79%
EPS Next 5Y1.39%
Revenue Next Year-6.17%
Revenue Next 2Y-1.57%
Revenue Next 3Y0.53%
Revenue Next 5Y2.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
MD is valuated cheaply with a Price/Earnings ratio of 7.92.
Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 93.20% of the companies listed in the same industry.
MD is valuated cheaply when we compare the Price/Earnings ratio to 26.48, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 8.10, which indicates a very decent valuation of MD.
Based on the Price/Forward Earnings ratio, MD is valued cheaper than 88.35% of the companies in the same industry.
MD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.92 | ||
| Fwd PE | 8.1 |
4.2 Price Multiples
MD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MD is cheaper than 90.29% of the companies in the same industry.
94.17% of the companies in the same industry are more expensive than MD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.42 | ||
| EV/EBITDA | 5.77 |
4.3 Compensation for Growth
MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.52
PEG (5Y)N/A
EPS Next 2Y8.97%
EPS Next 3Y6.79%
5. Dividend
5.1 Amount
No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
14.33
-0.15 (-1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change-0.15%
Ins Owners1.88%
Ins Owner Change7.87%
Market Cap1.23B
Analysts78.75
Price Target17.49 (22.05%)
Short Float %2.42%
Short Ratio2.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.94%
Min EPS beat(2)21.14%
Max EPS beat(2)32.73%
EPS beat(4)4
Avg EPS beat(4)26.19%
Min EPS beat(4)15.9%
Max EPS beat(4)34.96%
EPS beat(8)6
Avg EPS beat(8)10.2%
EPS beat(12)6
Avg EPS beat(12)3.22%
EPS beat(16)9
Avg EPS beat(16)4.71%
Revenue beat(2)0
Avg Revenue beat(2)-1.7%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.44%
Revenue beat(4)1
Avg Revenue beat(4)-0.9%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)1
Avg Revenue beat(12)-2.84%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)0%
PT rev (3m)-5.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.67%
EPS NY rev (1m)0%
EPS NY rev (3m)7.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.92 | ||
| Fwd PE | 8.1 | ||
| P/S | 0.63 | ||
| P/FCF | 5.42 | ||
| P/OCF | 5.03 | ||
| P/B | 1.48 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.77 |
EPS(TTM)1.81
EY12.63%
EPS(NY)1.77
Fwd EY12.35%
FCF(TTM)2.64
FCFY18.44%
OCF(TTM)2.85
OCFY19.86%
SpS22.59
BVpS9.7
TBVpS-4.87
PEG (NY)0.52
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROCE | 12.09% | ||
| ROIC | 9.55% | ||
| ROICexc | 11.91% | ||
| ROICexgc | 104.6% | ||
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A | ||
| FCFM | 11.7% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexcg growth 3Y26.95%
ROICexcg growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Debt/EBITDA | 2.47 | ||
| Cap/Depr | 73.88% | ||
| Cap/Sales | 0.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.31% | ||
| Profit Quality | 206.51% | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.87 |
F-Score7
WACC9.06%
ROIC/WACC1.05
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
EPS Next Y15.09%
EPS Next 2Y8.97%
EPS Next 3Y6.79%
EPS Next 5Y1.39%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
Revenue Next Year-6.17%
Revenue Next 2Y-1.57%
Revenue Next 3Y0.53%
Revenue Next 5Y2.24%
EBIT growth 1Y39.69%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year41.46%
EBIT Next 3Y15.15%
EBIT Next 5YN/A
FCF growth 1Y63.28%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y43.72%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%